UCLA Health joins nationwide clinical trial for acute myeloid leukemia
UCLA Health has joined an important national clinical trial that uses genetic testing to match people who have acute myeloid leukemia, or AML, with new therapies. UCLA ’s hospital system is the first in California to offer people the opportunity to participate.The Beat AML Master Trial will evaluate a precision-based medicine approach to treating the disease; it will allow people with the disease to have immediate access to new treatments that are currently in development without having to try more traditional approaches first. The approach could streamline a patient ’s course of treatment and, ultimately, save more lives.Acute myeloid leukemia, which affects 20,000 Americans annually, is responsible for more than 10,000 deaths a year, making it the most lethal form of blood cancer. “The ability to quickly connect patients with investigational drug therapies based on the individual genetic markers of their disease is the essence of precision medicine,” said Dr. Gary Schiller, the principal investigator in the UCLA arm of the trial and a member of theUCLA Jonsson Comprehensive Cancer Center. “We hope that this becomes a turning point in how we treat this disease, which is, in many ways, multiple diseases with multiple mutations involved.”The trial — for people 60 and older who are newly diagnosed with acute myeloid leukemia — is sponsored by the Leukemia&Lymphoma Society and is divided into nine treatment arms based on ...
CONCLUSIONS: Radiation therapy continues to be an integral component of the palliative armamentarium against painful metastases. Radiation oncologist, in conjunction with referral physicians, can tailor treatment plans to reflect the needs of a given patient. PMID: 30109789 [PubMed - in process]
CONCLUSIONS: A CNB to confirm mammographic or clinical findings of breast lesions is an accurate method to establish a pathological diagnosis of breast lesions. The accuracy is higher for invasive carcinomas than for non-invasive cancers. Excisional biopsies are necessary for lesions with anticipated sampling errors or when the core needle biopsy findings are discordant with clinical or mammographic findings. PMID: 30109786 [PubMed - in process]
Japan's Eisai Co Ltd said on Thursday it would price its cancer drug Lenvima at about $16,000 for a month's supply before discounts, after the U.S. Food and Drug Administration approved its use in patients with a common form of liver cancer.
At 76, Aretha Franklin died of pancreatic cancer, one of the most deadly forms of the disease. An expert explained to Daily Mail Online why, even with the safer form she had, pancreatic cancer kills.
Reuters Health Information
Will Woleben, six, from McKinney, Texas, was diagnosed with Leigh syndrome in April 2014. Now his parents are working to raise $300,000 to enroll him in a gene therapy trial.
Publication date: Available online 16 August 2018Source: Journal of Molecular Graphics and ModellingAuthor(s): Jakub Kollar, Vladimir FrecerAbstractInhibitors of histone deacetylase superfamily (HDAC), which induce cell cycle arrest, trigger cell death and reduce angiogenesis appear as promising anti-cancer drugs targeting the epigenetic regulation of gene expression. Approved HDAC inhibitors were found effective against haematological and solid malignancies, other HDACIs are currently in clinical trials for the treatment of neurological diseases or immune disorders. Among those, diarylcyclopropane hydroxamic acids (DCHA) ...
The oral therapy lenvatinib joins sorafenib as the only drugs approved for first-line treatment of patients with unresectable hepatocellular carcinoma.FDA Approvals
Cancer researchers and FBI agents have more in common than one might think at first blush. “We’re chasing down cancer clues, you’re chasing down people trying to do us harm, but ultimately, trying to find the truth,” Dr. Brian Druker, director of the OHSU Knight Cancer Institute, told a group of Oregon FBI officials on Wednesday. Druker was at the Oregon FBI headquarters near t he Portland International Airport as part of the agency’s leadership speaker series. Columbia Sportswear CEO…
Conclusion This is the first attempt to provide a glimpse on the pattern and distribution of HMs among AYA in Bangladesh. Future studies are essential to get a better insight on the epidemiology, biology, potential risk factors and treatment outcomes for the AYA age group.
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer in Young Adults | Cancer Therapy | Child Development | Children | Clinical Trials | Food and Drug Administration (FDA) | Gene Therapy | Genetics | Hematology | Hospitals | Learning | Leukemia | Lymphoma | Research | Universities & Medical Training